• Product name
    Anti-VLDL Receptor/VLDL-R antibody [1H10]
    See all VLDL Receptor/VLDL-R primary antibodies
  • Description
    Mouse monoclonal [1H10] to VLDL Receptor/VLDL-R
  • Host species
  • Tested applications
    Suitable for: WB, Flow Cyt, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide corresponding to Human VLDL Receptor/VLDL-R (C terminal).

  • General notes

    Blocks apoE4 binding.

    Previously labelled as VLDL Receptor. 



Our Abpromise guarantee covers the use of ab75591 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Use under non reducing condition. Predicted molecular weight: 96 kDa.
Flow Cyt Use 2µg for 106 cells.

ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.


ELISA Use at an assay dependent concentration.


  • Function
    Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation.
  • Tissue specificity
    Abundant in heart and skeletal muscle; also ovary and kidney; not in liver.
  • Involvement in disease
    Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures.
  • Sequence similarities
    Contains 3 EGF-like domains.
    Contains 8 LDL-receptor class A domains.
    Contains 6 LDL-receptor class B repeats.
  • Post-translational
    Ubiquitinated at Lys-839 by MYLIP leading to degradation.
  • Cellular localization
    Membrane. Membrane > clathrin-coated pit.
  • Information by UniProt
  • Database links
  • Alternative names
    • FLJ35024 antibody
    • Very low density lipoprotein receptor antibody
    • Very low-density lipoprotein receptor antibody
    • VLDL R antibody
    • VLDL receptor antibody
    • VLDL-R antibody
    • VLDLR antibody
    • VLDLR_HUMAN antibody
    • VLDLRCH antibody
    see all


  • Overlay histogram showing HEK293 cells stained with ab75591 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab75591, 2µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

  • Flow cytometry analysis of Human THP-1 cell lines, staining VLDL Receptor/VLDL-R (red histogram) with ab75591.

    Cells were taken from suspension culture and washed with PBS/BSA before fixation. Cells were blocked and permeabilized in 10% donkey serum/0.3 M glycine/0.1% BSA/0.1% Tween-20 in PBS for 20 mins at room temperature. The sample was incubated with the primary antibody (2 µg/106 cells in 0.1% BSA/0.1% Tween-20 in PBS) for 30 minutes at 22°C. A FITC-conjugated donkey anti-mouse polyclonal IgG (30 µg/ml) was used as the secondary antibody.

    Gating Strategy: FSC/SSC

    See Abreview


This product has been referenced in:
  • Gardner JK  et al. Lipid-laden partially-activated plasmacytoid and CD4(-)CD8a(+) dendritic cells accumulate in tissues in elderly mice. Immun Ageing 11:11 (2014). Flow Cyt ; Mouse . Read more (PubMed: 25089147) »
See 1 Publication for this product

Customer reviews and Q&As

1-3 of 3 Abreviews or Q&A

Western blot
Zebrafish Tissue lysate - whole (brain and embryo)
Gel Running Conditions
Reduced Denaturing (10%)
Loading amount
20 µg
brain and embryo
Blocking step
Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

Mrs. Fusun Balli

Verified customer

Submitted Jan 02 2013

Flow Cytometry
Human Cell (THP-1 cell line)
Yes - 0.1% Tween 20
Gating Strategy
Cell population was gated by FSC and SSC
THP-1 cell line
Cell harvesting/tissue preparation method: Cells were taken from suspension culture and washed with PBS/BSA before fixation
Sample buffer: 0.1% BSA in PBS
80% Methanol

Abcam user community

Verified customer

Submitted Oct 26 2012

Western blot
Human Cell lysate - whole cell (non-small lung carcinoma cells)
Gel Running Conditions
Non-reduced Denaturing (10%)
Loading amount
25 µg
non-small lung carcinoma cells
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 22°C

Abcam user community

Verified customer

Submitted Jul 02 2010

For licensing inquiries, please contact partnerships@abcam.com

Sign up